Literature DB >> 6149127

Assessment of adverse drug reactions in psychiatric hospitals.

R Grohmann, H Hippius, B Müller-Oerlinghausen, E Rüther, J Scherer, L G Schmidt, A Strauss, B Wolf.   

Abstract

A system for monitoring adverse drug reactions (ADR) in psychiatric inpatients was introduced in psychiatric hospitals in the FRG in May 1979. It consists of intensive drug monitoring (IDM) and a so-called "organized spontaneous reporting system" (OSR). ADR are rated separately according to impact on therapy and probability of causal relationship. With IDM all ADR (Grades I-III) are assessed in a randomly selected sample of inpatients. With OSR only ADR leading to discontinuation of the drugs in question (= ADR Grade III) are assessed. In 406 drug-treated inpatients monitored by IDM in the psychiatric hospitals of Berlin and Munich from May 1979 to Dec. 1981, ADR were observed in 60,4%. In 15% of IDM-patients ADR led to discontinuation of the drugs in question; with OSR the relative frequency of these Grade III ADR was 9,0% in 5096 patients monitored throughout the entire period. Life-threatening events were observed in 1,2% of patients undergoing IDM as well as 1.2% of those undergoing OSR. The most frequently observed ADR by IDM were sedation, extrapyramidal signs, disturbances of the autonomic nervous system and increase in transaminases, and by OSR Parkinsonism, akathisia, sedation, toxic delirium and increased transaminases. The relative frequency of Grade III ADR was similar for neuroleptics and antidepressants (5,4% and 5,3% in OSR); a very low relative frequency of ADR Grade III was found for tranquilizers and hypnotics (0,7% and 0,2%). Methodological aspects of this drug monitoring system are discussed in the light of current literature.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6149127     DOI: 10.1007/bf00541933

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  28 in total

1.  THE DESIGN AND LOGIC OF A MONITOR OF DRUG USE.

Authors:  D J FINNEY
Journal:  J Chronic Dis       Date:  1965-01

Review 2.  Postmarketing surveillance of new drugs: I. Review of objectives and methodology.

Authors:  W M Wardell; M C Tsianco; S N Anavekar; H T Davis
Journal:  J Clin Pharmacol       Date:  1979 Feb-Mar       Impact factor: 3.126

3.  Adverse reactions to the tricyclic-antidepressant drugs. Report from Boston Collaborative Drug Surveillance Program.

Authors: 
Journal:  Lancet       Date:  1972-03-04       Impact factor: 79.321

4.  Clinical biostatistics. 28. The biostatistical problems of pharmaceutical surveillance.

Authors:  A R Feinstein
Journal:  Clin Pharmacol Ther       Date:  1974-07       Impact factor: 6.875

5.  Assessment of adverse reactions within a drug surveillance program.

Authors:  I T Borda; D Slone; H Jick
Journal:  JAMA       Date:  1968-08-26       Impact factor: 56.272

6.  Intensive hospital monitoring of adverse reactions to drugs.

Authors:  N Hurwitz; O L Wade
Journal:  Br Med J       Date:  1969-03-01

7.  The ambiguity of adverse drug reactions.

Authors:  J Koch-Weser; E M Sellers; R Zacest
Journal:  Eur J Clin Pharmacol       Date:  1977-01-03       Impact factor: 2.953

8.  Patterns of drug use in psychiatric inpatient wards.

Authors:  C Swett
Journal:  J Clin Psychiatry       Date:  1979-11       Impact factor: 4.384

9.  An algorithm for the operational assessment of adverse drug reactions. III. Results of tests among clinicians.

Authors:  J M Leventhal; T A Hutchinson; M S Kramer; A R Feinstein
Journal:  JAMA       Date:  1979-11-02       Impact factor: 56.272

10.  Adverse drug reactions during hospitalization.

Authors:  R I Ogilvie; J Ruedy
Journal:  Can Med Assoc J       Date:  1967-12-09       Impact factor: 8.262

View more
  6 in total

1.  Incidence of adverse reactions to commonly prescribed psychopharmacological agents during early phase of therapy.

Authors:  A Kuruvilla; K Kuruvilla
Journal:  Indian J Psychiatry       Date:  1995-07       Impact factor: 1.759

2.  Agranulocytosis and significant leucopenia with neuroleptic drugs: results from the AMUP program.

Authors:  R Grohmann; L G Schmidt; C Spiess-Kiefer; E Rüther
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

3.  Consistency of assessment of adverse drug reactions in psychiatric hospitals: a comparison of an algorithmic and an empirical approach.

Authors:  L G Schmidt; P Dirschedl; R Grohmann; J Scherer; O Wunderlich; B Müller-Oerlinghausen
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

4.  Reliability of adverse drug reaction assessment in psychiatric inpatients.

Authors:  R Grohmann; P Dirschedl; J Scherer; L G Schmidt; O Wunderlich
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1985

5.  Adverse effects of clozapine.

Authors:  R Grohmann; E Rüther; N Sassim; L G Schmidt
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

6.  Detection of adverse drug reactions in a neurological department: comparison between intensified surveillance and a computer-assisted approach.

Authors:  Petra A Thuermann; Roland Windecker; Joachim Steffen; Markus Schaefer; Ute Tenter; Erich Reese; Hermann Menger; Klaus Schmitt
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.